Akademik Veri Yönetim Sistemi
Ankara Universitesi Eczacilik Fakultesi Dergisi, cilt.28, sa.2, ss.117-128, 1999 (Scopus)
Recently, there has been an increase in the interest in research on radioprotective agents. The aim is to achieve preferential protection of normal tissues against injury inflicted by ionising radiation or chemotherapy agents used to treat tumours. There are several classes of radioprotective compounds are present and still under investigation. Among these agents, commonly the sulfydryl-containing amifostine (Ethyol®) is currently the most widely used. Amifostine is a potent radioprotector of normal tissues and protect against radiation carcinogenesis. To be successful in tumor therapy, developing of new radioprotective compounds is urgently needed considering the amifostine is the only one effective compound in use in cancer treatment so far.